Yuqi Shen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yuqi Shen has a total of 105 co-authors. Here are the top co-authors by number of shared publications:
- Douglas R. Higgs
MRC Weatherall Institute of Molecular Medicine and Chinese Academy of Medical Sciences Oxford Institute, University of Oxford, Oxford, UK
3 shared publications - Abdullah O. Khan
MRC Weatherall Institute of Molecular Medicine and National Institute of Health Research (NIHR) Biomedical Research Centre Cancer Theme, University of Oxford, OX3 9DS Oxford, UK
2 shared publications Andrew J. H. Smith
Institute for Regeneration and Repair, MRC Centre for Regenerative Medicine, University of Edinburgh, Edinburgh, UK
2 shared publications- Aukje Marieke Oudelaar
Genome Organization and Regulation, Max Planck Institute for Multidisciplinary Sciences, Göttingen, Germany
2 shared publications Barbara Xella
MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UK
2 shared publications- Bethan Psaila
MRC Weatherall Institute of Molecular Medicine University of Oxford Oxford UK
2 shared publications
Latest Publications
- Open Access
- 11 September 2026
- Published by BMJ in BMJ Immunology
- Vol. 1 (1) , e000029
Belantamab mafodotin triggers immune invigoration in multiple myeloma via inflammatory and immunogenic cell death
Objective: Belantamab mafodotin, an antibody-drug conjugate targeting B-cell maturation antigen, has demonstrated significant clinical efficacy in combination therapies for relapsed/refractory multiple myeloma. Belantamab mafodotin exerts therapeutic effects through cytotoxicity of its payload, monomethyl auristatin F, and mediation of antibody-induced cell death. Long-term clinical responses were observed with monotherapy treatment, despite dose holds, suggesting adaptive immune system involvement. We aimed to explore mechanisms of belantamab mafodotin-triggered cell death and how this contributes to immune remodelling. Design: Cell lines, myeloma patient bone marrow and samples from belantamab mafodotin-treated patients were used to explore belantamab mafodotin-driven cell death and their downstream influence on the tumour microenvironment. Results: Here, we show that belantamab mafodotin induces markers of immunogenic and inflammatory cell death in vitro and ex vivo. Belantamab mafodotin monotherapy treatment triggers acute inflammation detectable in patient serum within 24 hours, with increases in granzyme B, CXCL9, CCL3 and CCL4 linked to response depth achieved. High expression of low-density lipoprotein receptor-related protein 1 (LRP1) and toll-like receptor 2 (TLR2), receptors that mediate immunogenic cell death on patients’ monocytoid (monocyte/macrophage) cells, suggests an important function of monocytoid cells to mediate the inflammation and immunogenic cell death cascades. Inflammation is followed by remodelling of the innate and adaptive immune system, a reduction in immune inhibitory signalling and the emergence of CD4 granzyme B-expressing cells in patients in remission versus those that relapse. Conclusion: Belantamab mafodotin’s ability to promote adaptive immune responses and its cytotoxic activity may help explain the durable responses observed in treated patients, despite dose and schedule modifications.
- 11 September 2026
- Published by BMJ in BMJ Immunology
- Vol. 1 (1) , e000029
Open AccessBelantamab mafodotin triggers immune invigoration in multiple myeloma via inflammatory and immunogenic cell death
Objective: Belantamab mafodotin, an antibody-drug conjugate targeting B-cell maturation antigen, has demonstrated significant clinical efficacy in combination therapies for relapsed/refractory multiple myeloma. Belantamab mafodotin exerts therapeutic effects through cytotoxicity of its payload, monomethyl auristatin F, and mediation of antibody-induced cell death. Long-term clinical responses were observed with monotherapy treatment, despite dose holds, suggesting adaptive immune system involvement. We aimed to explore mechanisms of belantamab mafodotin-triggered cell death and how this contributes to immune remodelling. Design: Cell lines, myeloma patient bone marrow and samples from belantamab mafodotin-treated patients were used to explore belantamab mafodotin-driven cell death and their downstream influence on the tumour microenvironment. Results: Here, we show that belantamab mafodotin induces markers of immunogenic and inflammatory cell death in vitro and ex vivo. Belantamab mafodotin monotherapy treatment triggers acute inflammation detectable in patient serum within 24 hours, with increases in granzyme B, CXCL9, CCL3 and CCL4 linked to response depth achieved. High expression of low-density lipoprotein receptor-related protein 1 (LRP1) and toll-like receptor 2 (TLR2), receptors that mediate immunogenic cell death on patients’ monocytoid (monocyte/macrophage) cells, suggests an important function of monocytoid cells to mediate the inflammation and immunogenic cell death cascades. Inflammation is followed by remodelling of the innate and adaptive immune system, a reduction in immune inhibitory signalling and the emergence of CD4 granzyme B-expressing cells in patients in remission versus those that relapse. Conclusion: Belantamab mafodotin’s ability to promote adaptive immune responses and its cytotoxic activity may help explain the durable responses observed in treated patients, despite dose and schedule modifications.
- 1 July 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (856) , eadz3553
CAR T cell therapy selectively depletes disease-driving mutant calreticulin cells in xenotransplants and human organoid models of myelofibrosis
Targeted immunotherapies have revolutionized outcomes for lymphoid malignancies, but success in myeloid neoplasms is limited by the lack of amenable targets and immunologically hostile tumor microenvironment (TME). Myeloproliferative neoplasms (MPNs) are chronic myeloid blood cancers, a third of which are driven by mutations in calreticulin. Calreticulin mutant protein (mutCALR) binds and activates thrombopoietin receptor (TpoR) and results in the display of the mutCALR-TpoR complex on the extracellular membrane of disease-driving cells, thus exposing a therapeutic vulnerability. Here, we present a chimeric antigen receptor T cell (CAR T cell) therapy that specifically targets mutCALR+ cells, both in vitro and in vivo. The CAR T cell therapy selectively depleted mutCALR+ stem cells in samples from patients with myelofibrosis without affecting healthy stem cells and improved survival in mutCALR leukemia xenograft models. To mimic myelofibrotic marrow, we developed a human “chimeroid” model and showed no decrease in the potency of CAR T cell–mediated target cell killing even in a fibrotic TME. We also devised a method to boost the cell surface expression of mutCALR in CD34+ cells isolated from patients with accelerated/blast phase MPNs (defined as >10% blasts in the peripheral blood or bone marrow), enhancing CAR T cell targeting. This study presents a therapeutic strategy with potential to eradicate mutCALR-driven malignancies and highlights an innovative strategy to evaluate blood cancer–targeting immunotherapies in a relevant TME.
- 1 July 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (856) , eadz3553
CAR T cell therapy selectively depletes disease-driving mutant calreticulin cells in xenotransplants and human organoid models of myelofibrosis
Targeted immunotherapies have revolutionized outcomes for lymphoid malignancies, but success in myeloid neoplasms is limited by the lack of amenable targets and immunologically hostile tumor microenvironment (TME). Myeloproliferative neoplasms (MPNs) are chronic myeloid blood cancers, a third of which are driven by mutations in calreticulin. Calreticulin mutant protein (mutCALR) binds and activates thrombopoietin receptor (TpoR) and results in the display of the mutCALR-TpoR complex on the extracellular membrane of disease-driving cells, thus exposing a therapeutic vulnerability. Here, we present a chimeric antigen receptor T cell (CAR T cell) therapy that specifically targets mutCALR+ cells, both in vitro and in vivo. The CAR T cell therapy selectively depleted mutCALR+ stem cells in samples from patients with myelofibrosis without affecting healthy stem cells and improved survival in mutCALR leukemia xenograft models. To mimic myelofibrotic marrow, we developed a human “chimeroid” model and showed no decrease in the potency of CAR T cell–mediated target cell killing even in a fibrotic TME. We also devised a method to boost the cell surface expression of mutCALR in CD34+ cells isolated from patients with accelerated/blast phase MPNs (defined as >10% blasts in the peripheral blood or bone marrow), enhancing CAR T cell targeting. This study presents a therapeutic strategy with potential to eradicate mutCALR-driven malignancies and highlights an innovative strategy to evaluate blood cancer–targeting immunotherapies in a relevant TME.
- Open Access
- 14 February 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
ATRX loss couples genome instability at a G-rich repeat to dysregulation of human alpha-globin expression
Germline mutations in the chromatin remodelling protein ATRX cause a severe developmental disorder associated with α-thalassemia. In addition, ATRX is amongst the twenty genes most frequently mutated in cancer. How ATRX mutations alter gene expression remains unclear. Using the α-globin locus as a model, here we show that ATRX deficiency downregulates α-globin in a subset of cells exhibiting DNA damage. A G-rich repeat at the α-globin locus serves as a potential site of G-quadruplex formation and DNA damage. ATRX binds this repeat co-transcriptionally, and its loss increases R-loop accumulation at this site, leading to local DNA damage and transcriptional disruption in cis . Deletion of this repeat abolishes this effect, while targeted DNA damage reinstates it. These findings reveal a mechanism linking ATRX’s role in genome stability to transcriptional regulation and uncover a molecular basis of human genetic disease mediated via a distal G-rich repeat.
- 14 February 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessATRX loss couples genome instability at a G-rich repeat to dysregulation of human alpha-globin expression
Germline mutations in the chromatin remodelling protein ATRX cause a severe developmental disorder associated with α-thalassemia. In addition, ATRX is amongst the twenty genes most frequently mutated in cancer. How ATRX mutations alter gene expression remains unclear. Using the α-globin locus as a model, here we show that ATRX deficiency downregulates α-globin in a subset of cells exhibiting DNA damage. A G-rich repeat at the α-globin locus serves as a potential site of G-quadruplex formation and DNA damage. ATRX binds this repeat co-transcriptionally, and its loss increases R-loop accumulation at this site, leading to local DNA damage and transcriptional disruption in cis . Deletion of this repeat abolishes this effect, while targeted DNA damage reinstates it. These findings reveal a mechanism linking ATRX’s role in genome stability to transcriptional regulation and uncover a molecular basis of human genetic disease mediated via a distal G-rich repeat.
- Open Access
- 26 September 2025
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 137 (8) , 1133-1136
Human Multi-Organoid Platform to Model Immune Dynamics in Cardiac Injury and Disease
- 26 September 2025
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 137 (8) , 1133-1136
Open AccessHuman Multi-Organoid Platform to Model Immune Dynamics in Cardiac Injury and Disease
- Open Access
- 16 April 2025
- Published by Springer Nature in Nature
- Vol. 642 (8067) , 508-518
Perturbing LSD1 and WNT rewires transcription to synergistically induce AML differentiation
Impaired differentiation is a hallmark of myeloid malignancies1,2. Therapies that enable cells to circumvent the differentiation block, such as all-trans retinoic acid (ATRA) and arsenic trioxide (ATO), are by and large curative in acute promyelocytic leukaemia3, but whether ‘differentiation therapy’ is a generalizable therapeutic approach for acute myeloid leukaemia (AML) and beyond remains incompletely understood. Here we demonstrate that simultaneous inhibition of the histone demethylase LSD1 (LSD1i) and the WNT pathway antagonist GSK3 kinase4 (GSK3i) robustly promotes therapeutic differentiation of established AML cell lines and primary human AML cells, as well as reducing tumour burden and significantly extending survival in a patient-derived xenograft mouse model. Mechanistically, this combination promotes differentiation by activating genes in the type I interferon pathway via inducing expression of transcription factors such as IRF7 (LSD1i) and the co-activator β-catenin (GSK3i), and their selective co-occupancy at targets such as STAT1, which is necessary for combination-induced differentiation. Combination treatment also suppresses the canonical, pro-oncogenic WNT pathway and cell cycle genes. Analysis of datasets from patients with AML suggests a correlation between the combination-induced transcription signature and better prognosis, highlighting clinical potential of this strategy. Collectively, this combination strategy rewires transcriptional programs to suppress stemness and to promote differentiation, which may have important therapeutic implications for AML and WNT-driven cancers beyond AML.
- 16 April 2025
- Published by Springer Nature in Nature
- Vol. 642 (8067) , 508-518
Open AccessPerturbing LSD1 and WNT rewires transcription to synergistically induce AML differentiation
Impaired differentiation is a hallmark of myeloid malignancies1,2. Therapies that enable cells to circumvent the differentiation block, such as all-trans retinoic acid (ATRA) and arsenic trioxide (ATO), are by and large curative in acute promyelocytic leukaemia3, but whether ‘differentiation therapy’ is a generalizable therapeutic approach for acute myeloid leukaemia (AML) and beyond remains incompletely understood. Here we demonstrate that simultaneous inhibition of the histone demethylase LSD1 (LSD1i) and the WNT pathway antagonist GSK3 kinase4 (GSK3i) robustly promotes therapeutic differentiation of established AML cell lines and primary human AML cells, as well as reducing tumour burden and significantly extending survival in a patient-derived xenograft mouse model. Mechanistically, this combination promotes differentiation by activating genes in the type I interferon pathway via inducing expression of transcription factors such as IRF7 (LSD1i) and the co-activator β-catenin (GSK3i), and their selective co-occupancy at targets such as STAT1, which is necessary for combination-induced differentiation. Combination treatment also suppresses the canonical, pro-oncogenic WNT pathway and cell cycle genes. Analysis of datasets from patients with AML suggests a correlation between the combination-induced transcription signature and better prognosis, highlighting clinical potential of this strategy. Collectively, this combination strategy rewires transcriptional programs to suppress stemness and to promote differentiation, which may have important therapeutic implications for AML and WNT-driven cancers beyond AML.
- Open Access
- 19 March 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1
Author Correction: The α-globin super-enhancer acts in an orientation-dependent manner
- 19 March 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1
Open AccessAuthor Correction: The α-globin super-enhancer acts in an orientation-dependent manner
- Open Access
- 25 January 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-18
The α-globin super-enhancer acts in an orientation-dependent manner
Individual enhancers are defined as short genomic regulatory elements, bound by transcription factors, and able to activate cell-specific gene expression at a distance, in an orientation-independent manner. Within mammalian genomes, enhancer-like elements may be found individually or within clusters referred to as locus control regions or super-enhancers (SEs). While these behave similarly to individual enhancers with respect to cell specificity, distribution and distance, their orientation-dependence has not been formally tested. Here, using the α-globin locus as a model, we show that while an individual enhancer works in an orientation-independent manner, the direction of activity of a SE changes with its orientation. When the SE is inverted within its normal chromosomal context, expression of its normal targets, the α-globin genes, is severely reduced and the normally silent genes lying upstream of the α-globin locus are upregulated. These findings add to our understanding of enhancer-promoter specificity that precisely activate transcription.
- 25 January 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-18
Open AccessThe α-globin super-enhancer acts in an orientation-dependent manner
Individual enhancers are defined as short genomic regulatory elements, bound by transcription factors, and able to activate cell-specific gene expression at a distance, in an orientation-independent manner. Within mammalian genomes, enhancer-like elements may be found individually or within clusters referred to as locus control regions or super-enhancers (SEs). While these behave similarly to individual enhancers with respect to cell specificity, distribution and distance, their orientation-dependence has not been formally tested. Here, using the α-globin locus as a model, we show that while an individual enhancer works in an orientation-independent manner, the direction of activity of a SE changes with its orientation. When the SE is inverted within its normal chromosomal context, expression of its normal targets, the α-globin genes, is severely reduced and the normally silent genes lying upstream of the α-globin locus are upregulated. These findings add to our understanding of enhancer-promoter specificity that precisely activate transcription.